Jagsonpal Pharmaceuticals Limited announced unaudited standalone earnings results for the second quarter and half year ended September 30, 2017. For the quarter, the company reported total income from operations of INR 289.068 million compared to INR 402.422 million a year ago. Total income was INR 290.789 million compared to INR 402.428 million a year ago. Loss before exceptional items and taxes was INR 39.447 million compared to profit of INR 6.293 million a year ago. Loss before tax was INR 39.447 million compared to profit of INR 6.293 million a year ago. Net loss for the period was INR 38.534 million or INR 1.47 per basic and diluted share before and after extraordinary items compared to profit of INR 5.033 million or INR 0.19 per basic and diluted share before and after extraordinary items a year ago. For the half year, the company reported total income from operations of INR 558.746 million compared to INR 805.715 million a year ago. Total income was INR 561.682 million compared to INR 805.724 million a year ago. Loss before exceptional items and taxes was INR 81.654 million compared to profit of INR 14.310 million a year ago. Loss before tax was INR 81.654 million compared to profit of INR 14.310 million a year ago. Net loss for the period was INR 80.741 million or INR 3.08 per basic and diluted share before and after extraordinary items compared to profit of INR 11.447 million or INR 0.44 per basic and diluted share before and after extraordinary items a year ago.